---
title: CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization
  resistance and immune homeostasis
date: '2024-01-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38227935/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240117170552&v=2.18.0
source: Blood
description: CPX-351, a liposomal combination of cytarabine plus daunorubicin, has
  been approved for the treatment of adults with newly diagnosed, therapy-related
  acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes as it
  improves survival and outcome of haematopoietic stem cell transplanted patients
  as compared to the continuous infusion of cytarabine plus daunorubicin (referred
  to as "7+3" combination). Because gut dysbiosis occurring in patients with AML during
  induction ...
disable_comments: true
---
CPX-351, a liposomal combination of cytarabine plus daunorubicin, has been approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes as it improves survival and outcome of haematopoietic stem cell transplanted patients as compared to the continuous infusion of cytarabine plus daunorubicin (referred to as "7+3" combination). Because gut dysbiosis occurring in patients with AML during induction ...